title: Pulmonary manifestations in Behçet disease: impaired natural killer cells activity.
abstract: BACKGROUND
  Behçet's disease (BD) is a systemic vasculitis with unknown aetiology, where, besides genetic predisposition, an immune dysregulation involving T and B lymphocytes and hyperactive neutrophils contribute to disease pathogenesis. The aim of this study was to determine the cytotoxicity of natural killer (NK) cells in bronchoalveolar lavage (BAL) from BD patients with pulmonary manifestations.
  
  
  METHODS
  BAL was performed in 27 patients with BD and pulmonary manifestations, 14 patients with Rheumatoid Arthritis (RA) and 23 healthy controls (HC). Related orphan receptor C (RORC) and forkheadbox P3 (FOXP3) mRNA transcript were determined in BAL by reverse transcription-polymerase chain reaction (RT-PCR). NK cells, NK cell cytotoxicity, and lymphokine-activated killer (LAK) activity against K562 cells were measured by flow cytometry. Proportions of NK precursors and expression of genes for IL-2 receptor β (IL-2Rβ; CD122), perforin, and granzyme in NK cells were measured by flow cytometry or RT-PCR.
  
  
  RESULTS
  The analysis of transcription factors revealed an increase in the RORC/FOXP3 ratio (Th17/Treg cells) in BAL from BD patients. Percentages of NK were significantly lower in BD than in RA patients and healthy controls. Purified NK cells derived from BD patients were found to have lower cytotoxicity and LAK activity than those from controls. This defect of NK cells in BD patients was related to down-regulation of perforin and granzyme expression in NK cells.
  
  
  CONCLUSIONS
  In BD patients, the increased RORC/FOXP3 ratio indicated an inflammatory state of the lung. NK cells were decreased together with an impairment of their activity due to a defective expression of granzyme and perforin. These abnormalities possibly contribute to immune system dysregulation found in BAL of BD patients with pulmonary manifestations.
authors.affiliation: Department of Basic Sciences, Division of Histology and Immunology, Medicine School of Tunis, Tunis El Manar University, 15 Rue DjebelLakdar, Tunis, 1007, Tunisia. kamel.hamzaoui@gmail.com.
authors.forename: Kamel
authors.initials: K
authors.lastname: Hamzaoui
authors.forename: Anissa
authors.initials: A
authors.lastname: Berraies
authors.forename: Wajih
authors.initials: W
authors.lastname: Kaabachi
authors.forename: Jamel
authors.initials: J
authors.lastname: Ammar
authors.forename: Agnès
authors.initials: A
authors.lastname: Hamzaoui
references.citation: Proc Natl Acad Sci U S A. 2004 Nov 23;101(47):16606-11
references.pmid: 15536127
references.citation: Rheumatol Int. 2010 Aug;30(10):1401-3
references.pmid: 19693504
references.citation: Tissue Antigens. 2007 Oct;70(4):307-13
references.pmid: 17767552
references.citation: J Immunol. 2012 Sep 15;189(6):2712-6
references.pmid: 22888135
references.citation: J Immunol. 2005 Nov 1;175(9):6133-42
references.pmid: 16237110
references.citation: Infect Immun. 1991 Apr;59(4):1434-41
references.pmid: 2004821
references.citation: Genet Test Mol Biomarkers. 2009 Jun;13(3):319-24
references.pmid: 19405872
references.citation: Scand J Immunol. 2012 Dec;76(6):559-66
references.pmid: 22928727
references.citation: J Neuroimmunol. 2006 Jun;175(1-2):160-8
references.pmid: 16624421
references.citation: Arthritis Rheum. 2009 Jun;60(6):1753-63
references.pmid: 19479851
references.citation: Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S8-14
references.pmid: 14727452
references.citation: J Neuroimmunol. 2003 Dec;145(1-2):127-34
references.pmid: 14644038
references.citation: J Mol Med (Berl). 2007 Oct;85(10):1047-56
references.pmid: 17426948
references.citation: J Autoimmun. 2012 Sep;39(3):206-15
references.pmid: 22704425
references.citation: Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5099-104
references.pmid: 20445113
references.citation: Arthritis Res Ther. 2010;12(3):R80
references.pmid: 20459787
references.citation: Am J Respir Crit Care Med. 1999 Aug;160(2):736-55
references.pmid: 10430755
references.citation: Clin Exp Rheumatol. 2004 Jul-Aug;22(4 Suppl 34):S59-63
references.pmid: 15515788
references.citation: J Invest Dermatol. 2010 Aug;130(8):2136-8
references.pmid: 20445554
references.citation: J Inflamm (Lond). 2012 Feb 13;9(1):3
references.pmid: 22330585
references.citation: Multidiscip Respir Med. 2012 Oct 23;7(1):37
references.pmid: 23092245
references.citation: Immunity. 2004 Apr;20(4):477-94
references.pmid: 15084276
references.citation: Nat Rev Immunol. 2007 Sep;7(9):703-14
references.pmid: 17717540
references.citation: Immunity. 2007 Apr;26(4):503-17
references.pmid: 17398124
references.citation: Arthritis Res Ther. 2009;11(1):R17
references.pmid: 19196489
references.citation: Lancet. 1990 May 5;335(8697):1078-80
references.pmid: 1970380
references.citation: Rheumatol Int. 2007 Mar;27(5):417-24
references.pmid: 17171346
references.citation: Science. 1987 Oct 2;238(4823):75-8
references.pmid: 3116668
references.citation: Oxid Med Cell Longev. 2010 Mar-Apr;3(2):122-8
references.pmid: 20716936
references.citation: Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S27-33
references.pmid: 17949548